Finoriq research workspace
BIOVIE INC. (BIVI) SEC Filings & Filing Highlights
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat. Review BIVI SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
- Company
- BIOVIE INC. (BIVI)
- Ticker
- BIVI
- Market Cap
- $10.7M
- Latest Price
- $1.425
- Industry
- Biotech & Pharma
BIOVIE INC. (BIVI) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for BIOVIE INC. (BIVI).
| Event | Form | Date |
|---|---|---|
| On November 10, 2025, at the 2025 annual meeting of stockholders (the “Annual Meeting”) of BioV...On November 10, 2025, at the 2025 annual meeting of stockholders (the “Annual Meeting”) of BioVie Inc. (the “Company”), the Company’s stock... | 8-K5.02 | 2025-11-13 |
| The following matters were considered at the Annual MeetingOn November 10, 2025, BioVie Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). On September 22, 202... | 8-K5.07 | 2025-11-12 |
| BioVie Inc. Announces Pricing of $12 Million Public OfferingBioVie Inc. Announces Pricing of $12 Million Public Offering | 8-K7.01 | 2025-08-11 |
| The Offering closed on August 11, 2025. The Company intends to use the proceeds for working cap...On August 7, 2025, BioVie Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with ThinkEquity LLC,... | 8-K1.01 | 2025-08-11 |
| BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of DirectorsBioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors | 8-K7.01 | 2025-07-23 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.